Stallergenes Greer Will Present New Evidence on Long-term Outcomes in Allergen Immunotherapy at EAACI 2026

Contributed by: Business Wire

Logo

Tags

Health

Other Health

Clinical Trials

General Health

Pharmaceutical

Biotechnology

EAACI 2026

More Like This

Stallergenes Greer Showcases New Data for Food and Respiratory Immunotherapy at 2024 EAACI Congress

Stallergenes Greer Showcases Developments in Respiratory and Food Allergy Care at EAACI 2025

Stallergenes Greer Publishes in the Lancet Regional Health-Europe Landmark EfficAPSI Real-world Study Confirming Significant Benefit of Its Liquid Sublingual AIT on the Onset and Progression of Allergic Asthma

Stallergenes Greer and Nuance Pharma Enter Exclusive Long-term Partnership for Actair® Sublingual Immunotherapy Tablet for the Treatment of House Dust Mite Allergy in China

Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards

Positive Adherence Impact of IPUMP® Connected Assistant for Sublingual Liquid Allergen Immunotherapy Treatment

Stallergenes Greer Foundation Announces Winners of 2023 Science Awards for Allergy

Staloral® Birch Phase III Study Successfully Meets Primary Endpoint, Demonstrating Efficacy in Children and Adolescents